$4 million from the Coalition for Epidemic Preparedness Innovations (CEPI) were not enough to create a vaccine against COVID-19. Additional $384 million funds will be poured into the project which is very famous among investors who seek significant profits. Novavax Q1 2020 revenue is much lower than the previous one. Anyway, the earnings are still negative despite the demand for vaccines getting higher to fight the pandemic.
Since May 11 the stock has been rising from $24.58 to $43.63. It could reach $50 next week as it will receive the funds to proceed with the creation of the vaccine. Watching Novavax stock is a very smart decision, but buying it may become the wisest.
CEO and Editor in Chief.
Living in the era of dynamic tech change Asan decided to stay tuned in changes that make any person find comfort and adapt to new devices. Furthermore, gaming became his passion for spending leisure time with his close ones. Although, he has a degree in Business Administration (majoring Finance) writing for technology and as well as finance has been one of the precious aspects of his life